Trial Profile
Phase I/II Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Busulfan; Filgrastim; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Dec 2021 Results (n=24) assessing the sorafenib safely added to the fractionated busulfan regimen and early data of efficacy with PFS at 1 year of follow up, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 12 Nov 2021 Planned End Date changed from 30 Jul 2022 to 31 Dec 2024.